本帖最后由 老马 于 2012-1-13 21:20 编辑
: s6 K7 ?* D, h- ]2 X' ?( o! b. |9 C( f9 z) n$ L
爱必妥和阿瓦斯丁的比较
9 ~, Y; T' `: `; ?: M
: Z: X( f# U/ B2 m( Jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/4 e2 ~% n5 z; u7 E( I
& e# X& f3 i3 L5 G0 T, d$ A: Z( [
* K, o0 y8 p6 y2 g/ x
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: r# N% C) L7 Z# }5 c! b$ ]9 {==================================================
C: G8 m# M& ~* X+ `# z+ mOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)8 J/ x$ N. y% I' m5 C o
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ F8 m. {- g2 x" X$ y) Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; i8 \+ u1 H2 {& P
|